secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001104659-24-060865
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Q1 net loss $0.74/share; cash $40M; WM study data in June
-------------------------------------------------------------------

- Net loss of $21.6M ($0.74/share) in Q1 2024 vs $8.6M ($0.76/share) in Q1 2023; cash $40.0M.
- CLOVER WaM pivotal study met primary endpoint: major response rate 61%; full data in June; NDA submission on track for H2 2024.
- Cash $40.0M as of March 31, 2024, expected to fund operations into Q4 2024; net cash used in operations ~$13M in Q1.
- Phase 1b pediatric high-grade glioma study enrolled first patient; data expected H2 2024.
- Preclinical data for alpha-emitting CLR 121225 in pancreatic cancer; phase 1 planned by Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924060865/0001104659-24-060865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924060865/tm2414381d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer